Search

Your search keyword '"Venema, Clasina M."' showing total 16 results
Start Over Author "Venema, Clasina M."
16 results on '"Venema, Clasina M."'

5. Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

Author

Mammatas, Lemonitsa H., Venema, Clasina M., Schröder, Carolina P., de Vet, Henrica C. W., van Kruchten, Michel, Glaudemans, Andor W. J. M., Yaqub, Maqsood M., Verheul, Henk M. W., Boven, Epie, van der Vegt, Bert, de Vries, Erik F. J., de Vries, Elisabeth G. E., Hoekstra, Otto S., Hospers, Geke A. P., and der Houven van Oordt, C. Willemien Menke-van

Published
2020
Full Text
View/download PDF

6. Visualizing bicalutamide effect on androgen receptor availability in patients with metastatic breast cancer

Author

Boers, Jorianne, Venema, Clasina M., de Vries, Erik F. J., Hospers, Geke A. P., Boersma, Hendrikus H., Rikhof, Bart, Dorbritz, Christine, Glaudemans, Andor W. J. M., Schroder, Carolina P., ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Molecular Neuroscience and Ageing Research (MOLAR), and Translational Immunology Groningen (TRIGR)

Published
2020

8. Additional file 1 of A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

Author

Jager, Agnes, Vries, Elisabeth G. E. De, C. Willemien Menke-Van Der Houven Van Oordt, Neven, Patrick, Venema, Clasina M., Glaudemans, Andor W. J. M., Yamei Wang, Bagley, Rebecca G., Conlan, Maureen G., and Aftimos, Philippe

Abstract

Additional file 1: Table S1. Elacestrant plasma concentrations over time. Figure S1. Patient disposition.

Published
2020
Full Text
View/download PDF

9. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition

Author

Arts-assistenten Radiologie, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Boers, Jorianne, Venema, Clasina M, de Vries, Erik F J, Glaudemans, Andor W J M, Kwee, Thomas C, Schuuring, Ed, Martens, John W M, Elias, Sjoerd G, Hospers, Geke A P, Schröder, Carolina P, Arts-assistenten Radiologie, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Boers, Jorianne, Venema, Clasina M, de Vries, Erik F J, Glaudemans, Andor W J M, Kwee, Thomas C, Schuuring, Ed, Martens, John W M, Elias, Sjoerd G, Hospers, Geke A P, and Schröder, Carolina P

Published
2020

10. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies

Author

Venema, Clasina M., primary, Mammatas, Lemonitsa H., additional, Schröder, Carolina P., additional, van Kruchten, Michel, additional, Apollonio, Giulia, additional, Glaudemans, Andor W.J.M., additional, Bongaerts, Alfons H.H., additional, Hoekstra, Otto S., additional, Verheul, Henk M.W., additional, Boven, Epi, additional, van der Vegt, Bert, additional, de Vries, Erik F.J., additional, de Vries, Elisabeth G.E., additional, Boellaard, Ronald, additional, Menke van der Houven van Oordt, Catharina W., additional, and Hospers, Geke A.P., additional

Published
2017
Full Text
View/download PDF

11. Translation of New Molecular Imaging Approaches to the Clinical Setting : Bridging the Gap to Implementation

Author

van Es, Suzanne C, Venema, Clasina M, Glaudemans, Andor W J M, Lub-de Hooge, Marjolijn N, Elias, Sjoerd G, Boellaard, Ronald, Hospers, Geke A P, Schröder, Carolina P, de Vries, Elisabeth G E, van Es, Suzanne C, Venema, Clasina M, Glaudemans, Andor W J M, Lub-de Hooge, Marjolijn N, Elias, Sjoerd G, Boellaard, Ronald, Hospers, Geke A P, Schröder, Carolina P, and de Vries, Elisabeth G E

Published
2016

12. Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation

Author

Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, van Es, Suzanne C, Venema, Clasina M, Glaudemans, Andor W J M, Lub-de Hooge, Marjolijn N, Elias, Sjoerd G, Boellaard, Ronald, Hospers, Geke A P, Schröder, Carolina P, de Vries, Elisabeth G E, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, van Es, Suzanne C, Venema, Clasina M, Glaudemans, Andor W J M, Lub-de Hooge, Marjolijn N, Elias, Sjoerd G, Boellaard, Ronald, Hospers, Geke A P, Schröder, Carolina P, and de Vries, Elisabeth G E

Published
2016

16. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.

Author

Jager, Agnes, de Vries, Elisabeth G. E., der Houven van Oordt, C. Willemien Menke-van, Neven, Patrick, Venema, Clasina M., Glaudemans, Andor W. J. M., Wang, Yamei, Bagley, Rebecca G., Conlan, Maureen G., and Aftimos, Philippe

Subjects
METASTATIC breast cancer, ESTROGEN receptors, TREATMENT effectiveness, POSITRON emission tomography computed tomography, POSTMENOPAUSE
Abstract

Background: Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmenopausal women with ER+ advanced breast cancer (ABC) using 16α-18F-fluoro-17β-estradiol positron emission tomography with low-dose computed tomography (FES-PET/CT).Methods: Eligible patients were postmenopausal women with ER+, HER2- ABC; tumor progression after ≥ 6 months of 1-3 lines of endocrine treatment for ABC; and measurable or evaluable disease. Two 8-patient cohorts were enrolled: one treated with 400 mg elacestrant once daily (QD) and one treated with 200 mg elacestrant QD with dose escalation to 400 mg QD after 14 days. Elacestrant was dosed continuously until progressive disease, toxicity, or withdrawal. FES-PET/CT was performed pre-dose at baseline and 4 h post-dose on day 14. The primary endpoint was the percentage difference in FES uptake in tumor lesions (maximum 20) after 14 days of treatment compared to baseline. Overall response was investigator-assessed by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1.Results: Patients (n = 16; median age, 53.5 years) had ABC with a median 2.5 prior lines of endocrine therapy. Median reduction in tumor FES uptake from baseline to day 14 was 89.1% (Q1, Q3: 75.1%, 94.1%) and was similar in both cohorts (89.1% [Q1, Q3: 67.4%, 94.2%], 200/400 mg and 88.7% [Q1, Q3: 79.5%, 94.1%], 400 mg). Residual ER availability (> 25% persistence in FES uptake) on day 14 was observed in 3 patients receiving 200/400 mg (3/78, 37.5%) and 1 patient receiving 400 mg (1/8, 12.5%). The overall response rate (ORR) was 11.1% (1 partial response), and clinical benefit rate (CBR) was 30.8%. Median percentage change in FES uptake did not correlate with ORR or CBR. Adverse events occurring in > 20% of the patients were nausea (68.8%), fatigue (50.0%), dyspepsia (43.8%), vomiting (37.5%), and decreased appetite, dysphagia, and hot flush (31.3% each). Most events were grade 2 in severity.Conclusion: Elacestrant 200 mg and 400 mg QD greatly reduced ER availability measured by FES-PET/CT. In a heavily pretreated population, elacestrant was associated with antitumor activity.Trial Registration: ClinicalTrials.gov, NCT02650817 . Registered on 08 January 2016. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results